Abatacept biosimilar (Dr. Reddy's Laboratories)

阿巴西普生物类似药 (印度瑞迪博士实验室)

Report date: 2024/02/05 13:26:17

Base Information

Drug NameAbatacept biosimilar (Dr. Reddy's Laboratories)
Drug Alias NameDRL-AB
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionCluster of differentiation 80 modulatorsCluster of differentiation 86 modulators
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDr.Reddy's Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDr.Reddy's Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AA24
Related LinksN/A